News

TB R&D Update: New treatment strategy using Bedaquiline in combination with heart medication, Verapamil

Researchers at the Center for Tuberculosis Research located at Johns Hopkins University School of Medicine have shown that heart medication, verapamil administered in combination with bedaquline lowers the toxicity of the TB drug without altering its efficacy. The paper, titled ‘Verapamil Increases the Bactericidal Activity of Bedaquiline Against Mycobacterium tuberculosis in the Mouse Model‘ was recently published in Antimicrobial Agents and Chemotherapy.

Although Bedaquiline is an effective anti-tuberculosis agent, it has significant liver and heart toxicity. Supplementing bedaquiline treatment in mice models with verapamil reduced not only the dosage required and thus toxicity, but also the emergence of antibiotic resistance, without sacrificing potency.

Scientists at the Tuberculosis Research Center plan to use this new data to design clinical trials.

Related Links

Verapamil Increases the Bactericidal Activity of Bedaquiline Against Mycobacterium tuberculosis in the Mouse Model

Study indicates new strategy to treat tuberculosis

New treatment strategy allows lower doses of toxic tuberculosis drug without compromising potency

Additional Links

Sirturo approved for conditional use in European Union to treat MDR-TB in adults

Efflux Inhibition with Verapamil Potentiates Bedaquiline in Mycobacterium tuberculosis

More News
30 Mar 2021
Médecins Sans Frontières (MSF) published a press release on World TB Day 2021 announcing their clinical trial, TB-Practecal , investigating novel treatment for MDR-TB has stopped enrolling earlier than originally planned due to promising results. The trial's independent data safety and monitoring...
3 Feb 2021
Last week, the World Health Organization (WHO) held a consultation to discuss the definition of extensively drug resistant (XDR) tuberculosis. The meeting was held to discuss novel treatment regimens and diagnostics for drug-resistant TB and determine its impact on the definition of XDR-TB. The...
10 Dec 2020
The Stop TB Partnership Working Group on New TB Vaccines (WGNV), Working Group on New TB Drugs (WGND), and New Diagnostics Working Group (NDWG) are developing an online course specifically designed for advocates and affected communities to provide a base of knowledge in TB research and to generate...